E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Invasive disease caused by Haemophilus type b and Neisseria meningitidis serogroups C and Y |
|
E.1.1.1 | Medical condition in easily understood language |
Inflammation of the brain and infection of the blood |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10028910 |
E.1.2 | Term | Neisseria meningitides meningitis |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10051931 |
E.1.2 | Term | Neisseria infection NOS |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
•To evaluate the long-term antibody persistence induced by 4 doses of Hib-MenCY-TT as compared to 4 doses of ActHIB given at 2, 4, 6, and 12 to 15 months of age in terms of the percentage of subjects with antibody to anti-PRP >= 0.15 µg/mL.
•To evaluate the long-term antibody persistence induced by 4 doses of Hib-MenCY-TT given at 2, 4, 6, and 12 to 15 months of age in terms of percentage of subjects with hSBA-MenC and hSBA-MenY titers >= 1:8.
•To evaluate the long-term antibody persistence induced by 3 doses of ActHIB given at 2, 4, 6 months of age, and a single dose of Hib-MenCY-TT at 12 to 15 months of age in terms of the percentage of subjects with anti-PRP concen-trations 0.15 µg/mL, hSBA-MenC and hSBA-MenY titers >= 1:8.
Note: The hSBA-MenC and hSBA-MenY endpoint of titers >= 1:8 reflect the primary endpoint for the analysis of persistence years 3 and 5. |
|
E.2.2 | Secondary objectives of the trial |
•To evaluate the long-term antibody persistence of the immune response to PRP in terms of the percent of subjects with anti-PRP >= 1.0 µg/mL and GMCs induced by 4 doses of Hib-MenCY-TT as compared to 4 doses of ActHIB given at 2, 4, 6, and 12 to 15 months of age.
•To evaluate the long-term antibody persistence of the immune response to PRP induced by 3 doses ActHIB at 2, 4, and 6 months of age followed by a single dose of Hib-MenCY-TT at 12 to 15 months of age as compared to 4 doses of ActHIB given at 2, 4, 6, and 12 to 15 months of age.
•To evaluate the long-term antibody persistence of anti-bodies to PRP, MenC and MenY in recipients of 4 doses of Hib-MenCY-TT given at 2, 4, 6, and 12 to 15 months of age as compared to recipients of 3 doses of ActHIB given at 2, 4, 6 months of age, and a single dose of Hib-MenCY-TT vaccine at 12 to 15 months of age. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Healthy male and female children who completed the previous four dose vaccination series study (NCT00129129). The age of the child at the 3 post-fourth dose timelines are as follows:
Year 1: 22 to 36 months of age.
Year 3: 44 to 60 months of age.
Year 5: 5 years post-dose 4 +/- 8 weeks
•Written informed consent obtained from the parent or guardian of the subject.
•Healthy subjects as established by medical history and clinical examination before entering into the study
•Having completed the fourth dose vaccination of study Hib-MenCY-TT-005/006 |
|
E.4 | Principal exclusion criteria |
Children should not have:
•received more than 4 doses of Hib or meningococcal serogroup C and Y vaccine
•had a history of H. influenzae type b, meningococcal serogroup C and Y diseases.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Anti-PRP antibody concentrations.
2. hSBA-MenC antibody titers
3. hSBA-MenY antibody titers |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. One year, three years, and five years after the fourth dose vaccination.
2. One year, three years, and five years after the fourth dose vaccination.
3. One year, three years, and five years after the fourth dose vaccination. |
|
E.5.2 | Secondary end point(s) |
1. Anti-PRP GMCs and antibody concentrations
2. hSBA-MenC and hSBA-MenY GMTs and antibody titers |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. One year, three years, and five years after the fourth dose vaccination.
2. One year, three years, and five years after the fourth dose vaccination. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |